The selective SOAT1 inhibitor nevanimibe (ATR-101, PD132301-2) has been investigated for the treatment of adrenal disorders [15, 16] and was recently tested in a phase I clinical trial against adrenocortical carcinoma [17]. This evidence concerns the gene SOAT1 and adrenal cortex carcinoma.